Show simple item record

dc.contributor.authorElkord, Eyad
dc.date.accessioned2009-06-23T11:39:32Z
dc.date.available2009-06-23T11:39:32Z
dc.date.issued2007
dc.identifier.citationImmunology and immunotherapy approaches for prostate cancer. 2007, 10 (3):224-36 Prostate Cancer Prostatic Dis.en
dc.identifier.issn1365-7852
dc.identifier.pmid17420764
dc.identifier.doi10.1038/sj.pcan.4500964
dc.identifier.urihttp://hdl.handle.net/10541/71226
dc.description.abstractSeveral mechanisms that impair the immune response to promote tumour progression are reported. These mechanisms aim to reduce the ability of antigen-presenting cells to present antigen and activate naïve T cells to support an active immune response or to create a suppressive environment that induce non-functional tumour-associated antigen-specific T cells. Prostate cancer (PC) alone accounts for 33% of incident cancer cases and about 9% of all cancer-related deaths among men in the USA during 2006. Whereas androgen deprivation has remained the first line of therapy for advanced PC, other therapies are still required due to progression to an androgen-resistant state and eventually loss of control in patients receiving hormonal therapy. Immunotherapy seems to be a promising approach to enhance tumour-specific T-cell responses in different cancers including prostate. More importantly, clinical trials in advanced PC patients have shown that immunotherapy may generate significant clinical responses. Immunology and immunotherapy aspects of PC with focus on prostate-specific antigen will be presented.
dc.language.isoenen
dc.subjectProstate Canceren
dc.subjectTumour Escapeen
dc.subject.meshAnimals
dc.subject.meshClinical Trials as Topic
dc.subject.meshDendritic Cells
dc.subject.meshHumans
dc.subject.meshImmunotherapy
dc.subject.meshLymphocyte Activation
dc.subject.meshMale
dc.subject.meshProstatic Neoplasms
dc.subject.meshT-Lymphocytes
dc.subject.meshTumor Escape
dc.titleImmunology and immunotherapy approaches for prostate canceren
dc.typeArticleen
dc.contributor.departmentCRUK Immunology Department, Paterson Institute for Cancer Research, University of Manchester, Manchester, UK. eelkord@picr.man.ac.uken
dc.identifier.journalProstate Cancer and Prostatic Diseasesen
html.description.abstractSeveral mechanisms that impair the immune response to promote tumour progression are reported. These mechanisms aim to reduce the ability of antigen-presenting cells to present antigen and activate naïve T cells to support an active immune response or to create a suppressive environment that induce non-functional tumour-associated antigen-specific T cells. Prostate cancer (PC) alone accounts for 33% of incident cancer cases and about 9% of all cancer-related deaths among men in the USA during 2006. Whereas androgen deprivation has remained the first line of therapy for advanced PC, other therapies are still required due to progression to an androgen-resistant state and eventually loss of control in patients receiving hormonal therapy. Immunotherapy seems to be a promising approach to enhance tumour-specific T-cell responses in different cancers including prostate. More importantly, clinical trials in advanced PC patients have shown that immunotherapy may generate significant clinical responses. Immunology and immunotherapy aspects of PC with focus on prostate-specific antigen will be presented.


This item appears in the following Collection(s)

Show simple item record